Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Conditions

• CANCER, NOS

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Lirilumab — DRUG
• Ipilimumab — DRUG

Study Details

To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with ipilimumab in subjects with select advanced (metastatic and/or unresectable) solid tumors.

Key Dates

First listed

Dec 17, 2012

Start date

Dec 31, 2012

Status verified

Jul 2015

Primary completion

Apr 30, 2015

Completion

Apr 30, 2015

Study Design

Enrollment

22 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Arm 1: Lirilumab + Ipilimumab
  Lirilumab and Ipilimumab on specific days

Primary Outcome Measure

Safety as measured by the rate of adverse events, and serious adverse events [ Time Frame: Approximately 510 days ]

Locations (6)

Find similar trials in Tampa, FL